Us Bancorp \De\ Altimmune, Inc. Transaction History
Us Bancorp \De\
- $77.3 Billion
- Q3 2024
A detailed history of Us Bancorp \De\ transactions in Altimmune, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 750 shares of ALT stock, worth $5,490. This represents 0.0% of its overall portfolio holdings.
Number of Shares
750
Previous 750
-0.0%
Holding current value
$5,490
Previous $4,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALT
# of Institutions
186Shares Held
39.3MCall Options Held
913KPut Options Held
743K-
Black Rock Inc. New York, NY5.32MShares$39 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$36.5 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$28.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$25 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$20.1 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $359M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...